WASHINGTON - Experts expressed enthusiasm after US health regulators approved the first new form of treatment for ...

New drug offers hope for patients with Schizophrenia that has long eluded effective treatment. Read on to know more.

With prices finalized for the first 10 Medicare Part D drugs selected for the initial round of pricing negotiations, ...

The FDA has approved Cobenfy, the first new schizophrenia treatment in 30 years, offering a novel approach with fewer side ...

Founded in 1993, The Motley Fool is a financial services company dedicated to making the world smarter, happier, and richer. The Motley Fool reaches millions of people every month through our premium ...

While momentous, the approval of Cobenfy could also draw attention to an age-old problem in American healthcare: Will insurance barriers keep patients from getting an effective medicine?

People with schizophrenia will soon have a new treatment option after the FDA approved its first new treatment for the mental ...

U.S. FDA Approves Bristol Myers Squibb’s COBENFY, a First-In-Class Muscarinic Agonist for the Treatment of Schizophrenia in Adults ...

On Thursday, the U.S. Food and Drug Administration approved COBENFY, an oral medication that marks the first new class of ...

The FDA has approved Cobenfy, a dual M1/M4 muscarinic agonist that offers a fundamentally different approach to treating ...

Bristol Myers Squibb has received U.S. FDA approval for a new schizophrenia drug, marking the first new antipsychotic medication in decades. The drug, Cobenfy, lacks warnings about increased mortality ...

The FDA has approved Cobenfy capsules from Bristol-Myers Squibb for the oral treatment of schizophrenia in adults. The medication, formerly known as KarXT, is the first antipsychotic medication to ...